866-997-4948(US-Canada Toll Free)

Published on : Jul 30, 2014

Denmark based Pharma group Zealand Pharma and Germany’s Boehringer Ingelheim have signed an accord to formulate new medicines for advanced and effective treatment of cardio-metabolic maladies. The collaboration between these two Pharma groups involves a new therapeutic peptide project from the list of preclinical programs of Zealand Pharma. 

Both these companies are aiming at investing about four and a half years on working towards developing, researching, identifying and discovering the newer peptide samples which work efficiently in the area of cardio-metabolic diseases. Only after the final identification of the suitable peptide samples, will they be taken forward for preclinical development. 

The deal states that the onus of conducting preclinical and clinical development, the required R&D and commercialization lies with the German drug maker Boehringer Ingelheim. 

Zealand Pharma is to receive an amount of 295 million for developing and marketing the very first compound under the deal and will also receive an additional flow of cash for any more compounds thenceforward. This Denmark based Pharma Company is entitled to receive funding for research and additional royalties on worldwide sale of the products developed from the collaboration. Also, Zealand Pharma holds with itself the rights of co-commercialization in Scandinavia.

The first deal that was signed between Boehringer Ingelheim and Zealand Pharma was in the year 2011 that dealt with dual-acting therapeutics of peptide to treat obesity and Type II diabetes.